This study is a open-lable, , single center, phase II clinical study. Target population is
patients with locally resectable osteosarcoma. Study objective is to compare the efficacy and
safety of camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate
in study population in China. Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.
In this study, eligible subject will be enrolled into study arm to accept study treatment.
Treatment cycles of chemotherapy will be at most 9 cycles which will be decided by
investigators. The percentage of the patient with tumor cell necrosis rate >90% determined by
the Independent Review Committee (IRC) will be the primary outcome measures.
Camrelizumab in Combination With Neoadjuvant Chemotherapy
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.